Medical therapy doses at hospital discharge in patients with existing and de novo heart failure

Abstract Aims Uptitrating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers (ACE‐I/ARBs), beta‐blockers, and mineralocorticoid receptor antagonists (MRAs) to optimal doses in heart failure with reduced ejection fraction (HFrEF) is associated with improved outcomes and recomme...

Full description

Bibliographic Details
Main Authors: Michael J. Diamant, Sean A. Virani, Winston J. MacKenzie, Andrew Ignaszewski, Mustafa Toma, Nathaniel M. Hawkins
Format: Article
Language:English
Published: Wiley 2019-08-01
Series:ESC Heart Failure
Subjects:
Online Access:https://doi.org/10.1002/ehf2.12454
id doaj-c4e3250cf08348d6a7dfe6e4522a057e
record_format Article
spelling doaj-c4e3250cf08348d6a7dfe6e4522a057e2020-11-24T23:53:30ZengWileyESC Heart Failure2055-58222019-08-016477478310.1002/ehf2.12454Medical therapy doses at hospital discharge in patients with existing and de novo heart failureMichael J. Diamant0Sean A. Virani1Winston J. MacKenzie2Andrew Ignaszewski3Mustafa Toma4Nathaniel M. Hawkins5Division of Cardiology University of British Columbia Vancouver CanadaDivision of Cardiology University of British Columbia Vancouver CanadaProvidence Health Care Analytics and Decision Support Vancouver CanadaDivision of Cardiology University of British Columbia Vancouver CanadaDivision of Cardiology University of British Columbia Vancouver CanadaDivision of Cardiology University of British Columbia Vancouver CanadaAbstract Aims Uptitrating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers (ACE‐I/ARBs), beta‐blockers, and mineralocorticoid receptor antagonists (MRAs) to optimal doses in heart failure with reduced ejection fraction (HFrEF) is associated with improved outcomes and recommended in guidelines. Studies of ambulatory patients found that a minority are prescribed optimal doses. However, dose at hospital discharge has rarely been reported. This information may guide quality improvement initiatives during and following discharge. Methods and results We assessed 370 consecutive patients with HFrEF hospitalized at two centres in Vancouver, Canada. Of those without contraindications, 86.4%, 93.4%, and 44.7% were prescribed an ACE‐I/ARB/sacubitril–valsartan, beta‐blocker, or MRA, respectively. The proportion of eligible patients prescribed target dose was respectively 28.6%, 31.7%, and 4.1%. Forty‐two of 248 eligible patients (16.9%) were prescribed ≥50% of target dose, and only three patients received target dosing of all three medication classes. In multivariate regression models, cardiologist involvement in care was independently associated with increased dose and prescription of ≥50% of target dose for all medications, whereas a history of HF was only predictive for beta‐blockers. Conclusions In a single‐region experience of hospitalized HFrEF patients, a high proportion of eligible patients were discharged on ACE‐I/ARB or beta‐blocker. Less than half were prescribed MRAs, and few were prescribed ≥50% or target dosing of all medications. Further exploration into barriers to medication uptitration, and improvement in processes of care, is needed.https://doi.org/10.1002/ehf2.12454Acute heart failureSystolic heart failureHFrEFGuideline‐directed medical therapyGuideline adherence
collection DOAJ
language English
format Article
sources DOAJ
author Michael J. Diamant
Sean A. Virani
Winston J. MacKenzie
Andrew Ignaszewski
Mustafa Toma
Nathaniel M. Hawkins
spellingShingle Michael J. Diamant
Sean A. Virani
Winston J. MacKenzie
Andrew Ignaszewski
Mustafa Toma
Nathaniel M. Hawkins
Medical therapy doses at hospital discharge in patients with existing and de novo heart failure
ESC Heart Failure
Acute heart failure
Systolic heart failure
HFrEF
Guideline‐directed medical therapy
Guideline adherence
author_facet Michael J. Diamant
Sean A. Virani
Winston J. MacKenzie
Andrew Ignaszewski
Mustafa Toma
Nathaniel M. Hawkins
author_sort Michael J. Diamant
title Medical therapy doses at hospital discharge in patients with existing and de novo heart failure
title_short Medical therapy doses at hospital discharge in patients with existing and de novo heart failure
title_full Medical therapy doses at hospital discharge in patients with existing and de novo heart failure
title_fullStr Medical therapy doses at hospital discharge in patients with existing and de novo heart failure
title_full_unstemmed Medical therapy doses at hospital discharge in patients with existing and de novo heart failure
title_sort medical therapy doses at hospital discharge in patients with existing and de novo heart failure
publisher Wiley
series ESC Heart Failure
issn 2055-5822
publishDate 2019-08-01
description Abstract Aims Uptitrating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers (ACE‐I/ARBs), beta‐blockers, and mineralocorticoid receptor antagonists (MRAs) to optimal doses in heart failure with reduced ejection fraction (HFrEF) is associated with improved outcomes and recommended in guidelines. Studies of ambulatory patients found that a minority are prescribed optimal doses. However, dose at hospital discharge has rarely been reported. This information may guide quality improvement initiatives during and following discharge. Methods and results We assessed 370 consecutive patients with HFrEF hospitalized at two centres in Vancouver, Canada. Of those without contraindications, 86.4%, 93.4%, and 44.7% were prescribed an ACE‐I/ARB/sacubitril–valsartan, beta‐blocker, or MRA, respectively. The proportion of eligible patients prescribed target dose was respectively 28.6%, 31.7%, and 4.1%. Forty‐two of 248 eligible patients (16.9%) were prescribed ≥50% of target dose, and only three patients received target dosing of all three medication classes. In multivariate regression models, cardiologist involvement in care was independently associated with increased dose and prescription of ≥50% of target dose for all medications, whereas a history of HF was only predictive for beta‐blockers. Conclusions In a single‐region experience of hospitalized HFrEF patients, a high proportion of eligible patients were discharged on ACE‐I/ARB or beta‐blocker. Less than half were prescribed MRAs, and few were prescribed ≥50% or target dosing of all medications. Further exploration into barriers to medication uptitration, and improvement in processes of care, is needed.
topic Acute heart failure
Systolic heart failure
HFrEF
Guideline‐directed medical therapy
Guideline adherence
url https://doi.org/10.1002/ehf2.12454
work_keys_str_mv AT michaeljdiamant medicaltherapydosesathospitaldischargeinpatientswithexistinganddenovoheartfailure
AT seanavirani medicaltherapydosesathospitaldischargeinpatientswithexistinganddenovoheartfailure
AT winstonjmackenzie medicaltherapydosesathospitaldischargeinpatientswithexistinganddenovoheartfailure
AT andrewignaszewski medicaltherapydosesathospitaldischargeinpatientswithexistinganddenovoheartfailure
AT mustafatoma medicaltherapydosesathospitaldischargeinpatientswithexistinganddenovoheartfailure
AT nathanielmhawkins medicaltherapydosesathospitaldischargeinpatientswithexistinganddenovoheartfailure
_version_ 1725469242919223296